| White River Eye Care | |
|
3609 Highway 367 N, Bald Knob, AR 72010-9404 | |
| (870) 834-3339 | |
| Not Available |
| Full Name | White River Eye Care |
|---|---|
| Type | Facility |
| Speciality | Optometrist |
| Location | 3609 Highway 367 N, Bald Knob, Arkansas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184041873 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | 2666 (Arkansas) | Primary |
| Provider Name | Jean A Stone |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1073691218 PECOS PAC ID: 0345365672 Enrollment ID: I20100916000019 |
News Archive
Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the generic version of Merck & Co.'s Zocor Tablets, a treatment for high cholesterol. The product will be distributed by Mylan Pharmaceuticals Inc.
Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.
Researchers at the Joslin Diabetes Center have shown that insulin-producing pancreatic beta cells can form after birth or after injury from progenitor cells within the pancreas that were not beta cells, a finding that contradicts a widely-cited earlier study that had concluded this is not possible.
When a patient with chronic pain is experiencing symptoms, relief is only thing on their mind. NSAIDs, or nonsteroidal anti-inflammatory drugs, can often provide that relief, however it's important to balance the potential benefits with the potential risks of these drugs.
› Verified 4 days ago
| Provider Name | Sam Cooke |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1780752022 PECOS PAC ID: 2062523541 Enrollment ID: I20110131000642 |
News Archive
Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the generic version of Merck & Co.'s Zocor Tablets, a treatment for high cholesterol. The product will be distributed by Mylan Pharmaceuticals Inc.
Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.
Researchers at the Joslin Diabetes Center have shown that insulin-producing pancreatic beta cells can form after birth or after injury from progenitor cells within the pancreas that were not beta cells, a finding that contradicts a widely-cited earlier study that had concluded this is not possible.
When a patient with chronic pain is experiencing symptoms, relief is only thing on their mind. NSAIDs, or nonsteroidal anti-inflammatory drugs, can often provide that relief, however it's important to balance the potential benefits with the potential risks of these drugs.
› Verified 4 days ago
| Provider Name | Hayden Harper Sowers |
|---|---|
| Provider Type | Practitioner - Optometry |
| Provider Identifiers | NPI Number: 1801184098 PECOS PAC ID: 2365611969 Enrollment ID: I20111027000378 |
News Archive
Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the generic version of Merck & Co.'s Zocor Tablets, a treatment for high cholesterol. The product will be distributed by Mylan Pharmaceuticals Inc.
Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.
Researchers at the Joslin Diabetes Center have shown that insulin-producing pancreatic beta cells can form after birth or after injury from progenitor cells within the pancreas that were not beta cells, a finding that contradicts a widely-cited earlier study that had concluded this is not possible.
When a patient with chronic pain is experiencing symptoms, relief is only thing on their mind. NSAIDs, or nonsteroidal anti-inflammatory drugs, can often provide that relief, however it's important to balance the potential benefits with the potential risks of these drugs.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| White River Eye Care 2402 Harrison St, Batesville, AR 72501-7421 Ph: (870) 834-3339 | White River Eye Care 3609 Highway 367 N, Bald Knob, AR 72010-9404 Ph: (870) 834-3339 |
News Archive
Palatin Technologies, Inc., announced today that it has received $978,000 in grants under the Patient Protection and Affordable Care Act of 2010 (PPACA), with $847,000 available immediately and $131,000 available no later than 30 days after Palatin's fiscal year ending June 30, 2011.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the generic version of Merck & Co.'s Zocor Tablets, a treatment for high cholesterol. The product will be distributed by Mylan Pharmaceuticals Inc.
Clinical trial results suggest significant benefits with the use of cabozantinib or nivolumab over everolimus for patients with advanced renal cell carcinoma, researchers reported at the European Cancer Congress in Vienna, Austria.
Researchers at the Joslin Diabetes Center have shown that insulin-producing pancreatic beta cells can form after birth or after injury from progenitor cells within the pancreas that were not beta cells, a finding that contradicts a widely-cited earlier study that had concluded this is not possible.
When a patient with chronic pain is experiencing symptoms, relief is only thing on their mind. NSAIDs, or nonsteroidal anti-inflammatory drugs, can often provide that relief, however it's important to balance the potential benefits with the potential risks of these drugs.
› Verified 4 days ago